Tarsus Doses First Participant in Phase 2 Clinical Trial of TP-05 (Lotilaner)

Tarsus Pharmaceuticals has dosed its first participant in the Calliope Phase 2 clinical trial for TP-05 (lotilaner). The trial aims to evaluate the efficacy and safety of the treatment for non-infectious uveitis. The trial is expected to enroll 240 patients across 75 sites globally. Tarsus is a clinical-stage biopharmaceutical company focused on developing innovative therapies for eye diseases.